Estradiol; Norethindrone Acetate; Relugolix Patent Expiration
Estradiol; Norethindrone Acetate; Relugolix is Used for managing heavy menstrual bleeding and pain associated with uterine fibroids in premenopausal women, as well as pain associated with endometriosis. It was first introduced by Sumitomo Pharma Switzerland Gmbh
Estradiol; Norethindrone Acetate; Relugolix Patents
Given below is the list of patents protecting Estradiol; Norethindrone Acetate; Relugolix, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Myfembree | US11793812 | Methods of treating endometriosis | May 03, 2038 | Sumitomo Pharma |
| Myfembree | US11033551 | Methods of treating uterine fibroids | Sep 29, 2037 | Sumitomo Pharma |
| Myfembree | US11957684 | Treatment of heavy menstrual bleeding associated with uterine fibroids | Sep 29, 2037 | Sumitomo Pharma |
| Myfembree | US11795178 | Compositions of thienopyrimidine derivatives | Sep 27, 2033 | Sumitomo Pharma |
| Myfembree | US7300935 | Thienopyrimidine compounds and use thereof | Jan 28, 2025 | Sumitomo Pharma |
| Myfembree | US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof | Jan 28, 2025 | Sumitomo Pharma |
| Myfembree | US9346822 | Thienopyrimidine compounds and use thereof |
Feb 17, 2024
(Expired) | Sumitomo Pharma |
Estradiol; Norethindrone Acetate; Relugolix's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List